Merck (MRK)
$92.90
0.25 (0.27%)
MRK Stock Quote Delayed 30 Minutes
Don’t Buy Pharma Stocks — Buy THESE Pharma Stocks
If your sliver of the pharma pie is too small, it's easy to fall into the "any old pharma stock will do" trap. Keep your eye on the prize with these must-own names.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$92.25
Market Cap
235.30B
PE Ratio
13.79
EPS
6.7363
Volume (Avg. Vol.)
12.30M
Day's Range
$91.78 - $93.21
52-Week Range
$81.04 - $132.70
Dividend & Yield
$3.12 (3.36%)
MRK Stock Predictions, Articles, and Merck News
Obesity: The Next Investment Driver
The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to profit.
Pfizer is Still a Pharmaceutical-Giant Buy
Despite a slowdown in sales as Lipitor becomes a generic drug, pharma giant Pfizer is still a very good buy, and a great play for your portfolio.
10 Stocks to Watch Get Ready to Release Earnings
Earnings releases from 10 key stocks can effect your portfolio decisions, so keep an eye on them over the next two days.
3 Ways to Buy Into a German Recovery
Germany's political machine has a lot to chew through in the next two years of elections, but these three stocks get my vote -- regardless of who wins.
Should I Buy Johnson & Johnson? 3 Pros, 3 Cons
Johnson & Johnson (JNJ) is off to a slow start in 2012, and its recent earnings report didn't do much to rouse the sleeping giant. Are JNJ shares worth buying?
Top 10 Dow Dividend Stocks for Retirement Investors
Anyone with a retirement portfolio should pay attention to Wall Street's elite group of blue-chip dividend stocks.
4 New ETFs: They’re All About Income
Last week's launches aimed straight at the income-investing crowd -- and included both equity funds of high dividend payers and a high-yield bond fund.
Why Investors Needn’t Fear the ‘Patent Cliff’
Expiring drug patents can cost pharma stocks billions of dollars, but companies and investors alike can prepare themselves well in advance.
Breaking Down Societe Generale’s Top 40 Dividend Stocks in the World
Societe Generale recently put out its annual list of the top 40 dividend payers across the globe. Here's a look at those companies, as well as a few trends.
10 Pharma Blue Chips to Buy
There are a number of great companies in pharma if you know where to look.
3 Crash-Proof Medical Stocks to Keep Your Portfolio’s Pulse
The recent rally won't last forever, but investors wanting to jump in can still do so -- and protect themselves -- by getting into these health-related equities.
20 Companies Increasing Dividends
Big energy, big beverage and big media are the top payout performers.
Top 10 Dow Dividend Stocks
Anyone with a retirement portfolio should have at least one eye turned to Wall Street's top group of blue-chip dividend stocks.
10 Pharma Stocks to Add to Your Portfolio…Stat
Investors have plenty of reasons to invest in the health care industry. With returns like these, it's no wonder investors are scrambling to own them.
CEOs with 20 Most Exorbitant Golden Parachutes in History
CEO pay and executive compensation gets a bad rap, in part due to the massive golden parachutes for execs. Here are the most egregious in history.
3 Health Care Plays With Healthy Dividends
These long-term picks fit the bill if you agree this sector's future is sound. Demographic trends alone make for a compelling argument.
The Tax Company Cometh on Strong
H&R Block has had a strong run-up to tax season, but there are still plenty of reasons to buy -- especially for income investors.
The Little Guys Are Pharma’s New Stars
Small and midsize drugmakers are where the action is -- in both research and M&A activity. For healthy dividends, however, Big Pharma still rules.
Are Pharma’s ‘Good Old Days’ Gone Forever?
You bet they are: Patent losses, a higher bar for FDA approvals, and slew of smaller, nimbler rivals have reshaped the industry.
Novartis Cutting 2,000 Jobs – So Much for Healthy Healthcare Stocks!
Novartis NYSE:NVS is cutting nearly 2,000 jobs in the United States. The reason? Patent expiration for its blockbuster blood pressure drug Diovan.
